BR9607583A - Plasmídio procariótico plasmídio pxl2638 célula procariótica processo de produção de genomas de adenovírus recombinantes processo de preparação de adenovírus recombinantes e composição farmacêutica - Google Patents

Plasmídio procariótico plasmídio pxl2638 célula procariótica processo de produção de genomas de adenovírus recombinantes processo de preparação de adenovírus recombinantes e composição farmacêutica

Info

Publication number
BR9607583A
BR9607583A BR9607583A BR9607583A BR9607583A BR 9607583 A BR9607583 A BR 9607583A BR 9607583 A BR9607583 A BR 9607583A BR 9607583 A BR9607583 A BR 9607583A BR 9607583 A BR9607583 A BR 9607583A
Authority
BR
Brazil
Prior art keywords
recombinant adenovirus
plasmid
prokaryotic
pharmaceutical composition
cell production
Prior art date
Application number
BR9607583A
Other languages
English (en)
Other versions
BR9607583B1 (pt
BRPI9607583B8 (pt
Inventor
Emmanuelle Vigne
Patrice Yeh
Cecile Orsini
Joel Crouzet
Laurent Naudin
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9476085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9607583(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of BR9607583A publication Critical patent/BR9607583A/pt
Publication of BR9607583B1 publication Critical patent/BR9607583B1/pt
Publication of BRPI9607583B8 publication Critical patent/BRPI9607583B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
BRPI9607583A 1995-02-13 1996-02-09 plasmídios procarióticos recombinantes. BRPI9607583B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9501632A FR2730504B1 (fr) 1995-02-13 1995-02-13 Procede de preparation de genomes d'adenovirus recombinants
PCT/FR1996/000215 WO1996025506A1 (fr) 1995-02-13 1996-02-09 Procede de preparation de genome d'adenovirus recombinants

Publications (3)

Publication Number Publication Date
BR9607583A true BR9607583A (pt) 1998-07-07
BR9607583B1 BR9607583B1 (pt) 2009-12-01
BRPI9607583B8 BRPI9607583B8 (pt) 2016-11-08

Family

ID=9476085

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9607583A BRPI9607583B8 (pt) 1995-02-13 1996-02-09 plasmídios procarióticos recombinantes.

Country Status (19)

Country Link
US (1) US6261807B1 (pt)
EP (1) EP0809704B1 (pt)
JP (1) JP3842818B2 (pt)
KR (1) KR100575521B1 (pt)
AT (1) ATE405662T1 (pt)
AU (1) AU716777B2 (pt)
BR (1) BRPI9607583B8 (pt)
CA (1) CA2210956C (pt)
CZ (1) CZ294338B6 (pt)
DE (1) DE69637648D1 (pt)
FI (1) FI120046B (pt)
FR (1) FR2730504B1 (pt)
HU (1) HU222808B1 (pt)
IL (1) IL117115A (pt)
MX (1) MX9705937A (pt)
NO (1) NO327980B1 (pt)
SK (1) SK286965B6 (pt)
WO (1) WO1996025506A1 (pt)
ZA (1) ZA961153B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020136708A1 (en) * 1993-06-24 2002-09-26 Graham Frank L. System for production of helper dependent adenovirus vectors based on use of endonucleases
DE19620687A1 (de) * 1996-05-22 1997-11-27 Centeon Pharma Gmbh Neuer adenoviraler Vektor für den Transfer humaner Gene in vivo
ATE256196T1 (de) * 1997-06-09 2003-12-15 Genvec Inc Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten
EP1015620B1 (en) 1997-09-23 2005-08-31 Genvec, Inc. Dual selection cassette and plasmids containing same
CA2340276A1 (en) * 1998-08-28 2000-03-09 Duke University Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
CA2363061A1 (en) * 1999-02-18 2000-08-24 Merck & Co., Inc. Production of helper dependent adenovirus vectors based on use of endonucleases
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
WO2001059071A2 (en) * 2000-02-09 2001-08-16 Genvec, Inc. Methods of preparing and using a viral vector library
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6573092B1 (en) 2000-10-10 2003-06-03 Genvec, Inc. Method of preparing a eukaryotic viral vector
AUPR518501A0 (en) 2001-05-22 2001-06-14 Unisearch Limited Yin yang-1
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
US8304189B2 (en) 2003-12-01 2012-11-06 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
PL2002003T3 (pl) 2005-05-27 2016-06-30 Ospedale San Raffaele Srl Wektor genetyczny zawierający mi-RNA
UA100692C2 (ru) 2007-05-02 2013-01-25 Мериал Лимитед Днк-плазмиды, имеющие повышенную экспрессию и стабильность
US20110269119A1 (en) * 2009-10-30 2011-11-03 Synthetic Genomics, Inc. Encoding text into nucleic acid sequences
AU2014338864C1 (en) * 2013-10-25 2020-07-16 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
US10076562B2 (en) 2016-04-19 2018-09-18 The Board Of Regents Of The University Of Texas System Methods for treating plague
WO2018054822A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New swine influenza vaccine
WO2018057441A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh Canine adenovirus vectors
KR102618843B1 (ko) 2016-09-20 2024-01-02 베링거잉겔하임베트메디카게엠베하 신규한 ehv 삽입 부위 orf70
MY199909A (en) 2016-09-20 2023-11-29 Boehringer Ingelheim Vetmedica Gmbh Promoters

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2249761T3 (es) * 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
BR9405507A (pt) * 1993-07-13 1999-05-25 Rhone Poulenc Rorer Sa Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
WO1996013597A2 (en) * 1994-10-28 1996-05-09 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
FR2727689A1 (fr) * 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral

Also Published As

Publication number Publication date
HU222808B1 (hu) 2003-10-28
WO1996025506A1 (fr) 1996-08-22
HUP9800260A1 (hu) 1998-05-28
SK286965B6 (sk) 2009-08-06
CZ255497A3 (en) 1997-11-12
EP0809704B1 (fr) 2008-08-20
FR2730504A1 (fr) 1996-08-14
FI120046B (fi) 2009-06-15
IL117115A0 (en) 1996-06-18
US6261807B1 (en) 2001-07-17
MX9705937A (es) 1997-10-31
AU4723596A (en) 1996-09-04
BR9607583B1 (pt) 2009-12-01
CA2210956C (fr) 2010-06-08
JPH11500007A (ja) 1999-01-06
AU716777B2 (en) 2000-03-09
NO973663D0 (no) 1997-08-08
ZA961153B (en) 1996-08-23
JP3842818B2 (ja) 2006-11-08
IL117115A (en) 2005-06-19
FI973309L (fi) 1997-08-12
DE69637648D1 (de) 2008-10-02
HUP9800260A3 (en) 2000-12-28
KR19980702139A (ko) 1998-07-15
SK110097A3 (en) 1998-06-03
KR100575521B1 (ko) 2006-10-24
EP0809704A1 (fr) 1997-12-03
FI973309A0 (fi) 1997-08-12
NO973663L (no) 1997-08-08
CZ294338B6 (cs) 2004-12-15
CA2210956A1 (fr) 1996-08-22
ATE405662T1 (de) 2008-09-15
FR2730504B1 (fr) 1997-03-28
NO327980B1 (no) 2009-11-02
BRPI9607583B8 (pt) 2016-11-08

Similar Documents

Publication Publication Date Title
BR9607583A (pt) Plasmídio procariótico plasmídio pxl2638 célula procariótica processo de produção de genomas de adenovírus recombinantes processo de preparação de adenovírus recombinantes e composição farmacêutica
AU7054798A (en) Modified adenoviral fiber and target adenoviruses
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
EP1312679B8 (en) Recombinant MVA virus, and the use thereof
ATE238038T1 (de) Liposomale formulierungen von mitoxantron
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
AU641568B2 (en) Polypeptide,DNA fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same
FI954966L (fi) Puutteellisia yhdistelmä-DNA-adenoviruksia kasvainten geeniterapiassa
EE200000152A (et) Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
WO1999032516A3 (en) Pharmaceutical compositions containing the long pentraxin ptx3
AU7155296A (en) Interleukin-19
EP0437610A4 (en) Novel physiologically active polypeptide, recombinant plasmid, recombinant microbial cells, medicinal composition, and process for recovering purified polypeptide
BR9708227A (pt) Processo de purificação de dna duplo filamento de pureza farmacêutica preparação de dna plasmídico recombinante e composição farmacêutica
WO1994003601A3 (en) Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
FI971100L (fi) Menetelmä yhdistelmä-DNA-proteiinien, plasmidien ja modifioitujen solujen tuottamiseksi
DK0769056T3 (da) Ikke-splejsende verianter af gp350/220
NO840952L (no) Fremgangsmaate til fremstilling av et humant interferon-gamma-polypeptid, rekombinant plasmid omfattende et dna-fragment som koder for peptidet, og mikroorganisme transfermert med plasmidet
CA2148369A1 (en) Actinobacillus pleuropneumoniae outer membrane lipoprotein a and uses thereof
FI964784L (fi) Yhdistelmä-DNA-viruksia, valmistus ja käyttö geeniterapiassa
AU2438688A (en) Human t-pa(u-pa) substitution-mutant proteins, recombinant dna coding therefor, transfected host cells, preparation of the mutant proteins, and pharmaceutical compositions

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: AVENTIS PHARMA S.A. (FR)

Free format text: ALTERADO DE: RHONE-POULENC RORER S.A.

B25A Requested transfer of rights approved

Owner name: GENCELL S.A. (FR)

Free format text: TRANSFERIDO DE: AVENTIS PHARMA S.A.

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: GENCELL S.A. (FR)

Free format text: A FIM DE ATENDER O SOLICITADO NA PETICAO NO 030274/RJ DE 31/05/2004, QUEIRA APRESENTAR DOCUMENTO DE ALTERACAO DE NOME.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: GENCELL S.A. (FR)

Free format text: REFERENTE A RPI 1858 COD. (25.6) DE 15/08/2006, POR TER SIDO INDEVIDO.

B25D Requested change of name of applicant approved

Owner name: GENCELL SAS (FR)

Free format text: ALTERADO DE: GENCELL S.A.

B25D Requested change of name of applicant approved

Owner name: CENTELION (FR)

Free format text: ALTERADO DE: GENCELL SAS

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2009, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.68486/2013 ORIGEM: JUIZO DA 25A VARA FEDERAL DE SAO PAULO PROCESSO NO 0017574-93.2013.4.03.6100 ACAO DE NULIDADE DE PATENTE AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: BAYER SAS, CENTELION E CENTELION S.A., CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, MERCK SERONO S.A. E SAMJIN PHARMACEUTICAL CO. LTD.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.068486/2013 SECAO JUDICIARIA DE SAO PAULO - 25A VARA FEDERAL CIVEL DE SAO PAULO PROCESSO NO0017574-93.2013.403.6100 AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: BAYER SAS, CENTELION, CENTELION S.A, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, MERCK SERONO S.A E SAMJIN PHARMACEUTICAL CO. LTDA DECISAO: JULGO PROCEDENTE O PEDIDO FORMULADO PARA DECLARAR A NULIDADE PARCIAL DAS PATENTES PI 9607583-0, PI 9610511-9, PI 9707889-1 E PI 9604907-3 E DETERMINO A RETIFICACAO DOS RESPECTIVOS PRAZOS DE VIGENCIA DE MODO A OBSERVAR A O DISPOSTO NO PARAGRAFO UNICO DO ARTIGO 229 DA LEI NO 9.279-96, EM INTERPRETACAO CONJUNTA COM O CAPUT DO ARTIGO 40 DO MESMO DIPLOMA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2030 DE 01/12/2009, QUANTO AO PRAZO DE VALIDADE POR DETERMINACAO DA 25A VARA CIVEL FEDERAL DE SAO PAULO, PROC. 0017574-93.2013.403.6100 - ACAO ORDINARIA - INPI 52400.068486/2013-05.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI NO 52400.009771/2015-48 PROCESSO JUDICIAL: 0017574-93.2013.4.03.6100 NUP: 00848.000050/2015-10 (REF. 0017574-93.2013.4.03.6100) PARECER DE FORCA EXECUTORIA N. 00012/2020/EEFIN NAP/EEFINSP/PGF/AGU INTERESSADOS: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI E OUTROS DECISAO: O JUIZO DA 25A VARA CIVEL FEDERAL DE SAO PAULO JULGOU O PEDIDO PARCIALMENTE PROCEDENTE, PARA DECLARAR A NULIDADE PARCIAL DAS PATENTES PI 9607583-0, PI 9610511-9, E PI 9707889-1, ADEQUANDO AS PATENTES AOS ARTIGOS 229, P. U., E 40, CAPUT, DA LEI N. 9.279-96. ESTA DECISAO FOI POSTERIORMENTE CONFIRMADA PELO TRF DA 3A REGIAO, COM TRANSITO EM JULGADO EM 23 DE JULHO DE 2019.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 09/02/2016